Evidence map›Paper›PMID 26335247›Full record

ArticleCritical care (London, England)2015

Outcomes associated with bacteremia in the setting of methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study.

Andrew F Shorr, Marya D Zilberberg, Scott T Micek, Marin H Kollef

Open access · goldAbstract read
In one paragraph

Article in Critical care (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Hospital-onset methicillin-resistantInfection control and hospital epidemiology · 2026
    Article
  3. Effect of a rapid bacteraemia response programme onJAC-antimicrobial resistance · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Rapid detection ofFrontiers in microbiology · 2022
    Article
  8. Article
  9. Observational
  10. Observational
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Andrew F ShorrDepartment of Pulmonary and Critical Care Medicine, Washington Hospital Center, 110 Irving St NW, Washington, DC, 20010, USA. andrew.shorr@gmail.com.
Marya D ZilberbergEviMed Research Group, LLC, PO Box 303, Goshen, MA, USA. evimedgroup@gmail.com.
Scott T MicekSt. Louis College of Pharmacy, 4588 Parkview Place, St. Louis, MO, 63110, USA. Scott.micek@stlcop.edu.
Marin H KollefDivision of Pulmonary and Critical Care Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8052, St. Louis, MO, 63110, USA. mkollef@dom.wustl.edu.
MedStar Washington Hospital Center · USUniversity of Health Sciences and Pharmacy · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMethicillin-resistant Staphylococcus aureus (MRSA) remains an important pathogen in pneumonia. Bacteremia may secondarily complicate MRSA pneumonia. The epidemiology and outcomes associated with bacteremia in the setting of MRSA pneumonia are unknown. We sought to describe the prevalence of bacteremia in MRSA pneumonia and its impact on hospital mortality and length of stay (LOS).

methodsWe conducted a single-center retrospective cohort study (2008-2013) including adult patients hospitalized with pneumonia caused by MRSA. We defined pneumonia based on clinical criteria and all cases were culture confirmed. MRSA bacteremia was identified based on positive blood cultures. Pneumonia was categorized as either community-onset (CO, occurring at presentation or within 2 days of admission) or hospital-onset (HO, occurring > 2 days after admission). We compared bacteremic and non-bacteremic groups with respect to their demographic and clinical characteristics and outcomes. A logistic regression and a generalized linear model (GLM) were constructed to examine the impact of bacteremia on hospital mortality and post-pneumonia onset LOS, respectively.

resultsAmong the 765 patients with MRSA pneumonia (33.1% CO), 93 (12.2%) had concurrent bacteremia (37.6% CO). Patients with bacteremia were similar to non-bacteremic subjects based on demographic and clinical characteristics with the exception of frequency of a hospitalization within prior 180 days (48.4% bacteremic and 37.7% non-bacteremic, p = 0.047), prevalence of chronic liver disease (17.2% vs. 9.5%, p = 0.030), and the mean APACHE II score at the onset of pneumonia (17.5 ± 6.0 vs. 16.1 ± 6.0, p = 0.045). Both unadjusted mortality (33.7% vs. 23.8%, p = 0.067) and median post-pneumonia LOS (18.2 vs. 12.2 days, p < 0.001) were greater in the bacteremic than the non-bacteremic group. In a logistic regression, bacteremia showed a trend toward an association with increased mortality (odds ratio 1.56, 95% confidence interval 0.93 to 2.61). Concomitant bacteremia was independently associated with a 10.3-day increase in the post-pneumonia hospital LOS (95% confidence interval 6.7 to 13.9 days).

conclusionsConcurrent bacteremia occurred with moderate frequency in the setting of hospitalization with MRSA pneumonia. Although bacteremia did not appear to independently impact mortality, this was likely due to our study's limited sample size. However, bacteremia complicating MRSA pneumonia added between 1 and 2 weeks to the hospital LOS.

Indexed as

Methicillin-Resistant Staphylococcus aureusAgedBacteremiaCommunity-Acquired InfectionsCross InfectionFemaleHospital MortalityHumansLength of StayMaleMiddle AgedPneumonia, StaphylococcalRetrospective Studies

Identifiers

PMID26335247
PMCPMC4558880
OpenAlexW1926656083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.